Akari Therapeutics PLC (AKTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.16 (-7.24%), Market cap $0.00B, 52-week low–high $0.12 ~ $6.58.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bisp
Financial statements, price targets, institutional (13F) holdings and related news for Akari Therapeutics PLC are updated in real time on BlackAll Trade.
Akari Therapeutics PLC trades at $9.16 (-7.24%). Real-time quotes and charts are available on BlackAll Trade.
Akari Therapeutics PLC has a market cap of about $0.00B.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immun